Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock fell 3.41% (As on February 6, 11:43:05 AM UTC-4, Source: Google Finance) though the company surpasses market’s expectations for the fourth quarter of FY 23. The company has announced its latest clinical trial results, highlighting the success of its vanzacaftor/tezacaftor/deutivacaftor regimen, known as the vanza triple, in treating cystic fibrosis (CF). The Phase 3 trials, which encompassed participants aged 12 years and older, met all primary and key secondary endpoints, showcasing non-inferiority to the current treatment TRIKAFTA in improving lung function and superiority in reducing sweat chloride levels, a marker of CFTR protein function. The company revealed that the vanza triple was generally well-received across all three studies, with comparable safety profiles to TRIKAFTA. The findings were particularly promising in a separate study involving children aged 6 to 11, indicating the potential for early treatment to prevent disease progression. Vertex has also received regulatory approvals for CASGEVY in the U.S., Great Britain, Bahrain, and the Kingdom of Saudi Arabia (KSA) for the treatment of both SCD and TDT.

VRTX in the fourth quarter of FY 23 has reported the adjusted earnings per share of $4.20, beating the analysts’ estimates for the adjusted earnings per share of $4.10. The company had reported the adjusted revenue growth of 9 percent to $2.52 billion in the fourth quarter of FY 23, beating the analysts’ estimates for revenue by 0.76%. Net product revenue in the fourth quarter of 2023 increased 8% to $1.57 billion in the U.S. and increased 12% to $943 million outside the U.S., compared to the fourth quarter of 2022. Combined GAAP and Non-GAAP R&D, Acquired IPR&D and SG&A expenses were $1.2 billion and $1.0 billion, respectively, compared to $984 million and $872 million, respectively, in the fourth quarter of 2022. The increases were due to increased investment in support of multiple programs that have advanced in mid- and late-stage clinical development and the costs to support launches of Vertex’s therapies globally. Combined GAAP R&D, Acquired IPR&D and SG&A expenses also included increased stock-based compensation expense compared to the fourth quarter of 2022. Cash, cash equivalents and total marketable securities as of December 31, 2023 were $13.7 billion, compared to $10.9 billion as of December 31, 2022. The increase was primarily due to income from operations that was driven by strong revenue growth, and interest income, partially offset by income tax payments and repurchases of our common stock pursuant to our share repurchase program.